tetano
Editor, Senior Moderator
MMWR Morb Mortal Wkly Rep
. 2020 Dec 11;69(49):1857-1859.
doi: 10.15585/mmwr.mm6949e1.
The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020
Kathleen Dooling, Nancy McClung, Mary Chamberland, Mona Marin, Megan Wallace, Beth P Bell, Grace M Lee, H Keipp Talbot, Jos? R Romero, Sara E Oliver
Abstract
The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic that has disrupted all sectors of society. Less than 1 year after the SARS-CoV-2 genome was first sequenced, an application* for Emergency Use Authorization for a candidate vaccine has been filed with the Food and Drug Administration (FDA). However, even if one or more vaccine candidates receive authorization for emergency use, demand for COVID-19 vaccine is expected to exceed supply during the first months of the national vaccination program. The Advisory Committee on Immunization Practices (ACIP) advises CDC on population groups and circumstances for vaccine use.[SUP]†[/SUP] ACIP convened on December 1, 2020, in advance of the completion of FDA's review of the Emergency Use Authorization application, to provide interim guidance to federal, state, and local jurisdictions on allocation of initial doses of COVID-19 vaccine. ACIP recommended that, when a COVID-19 vaccine is authorized by FDA and recommended by ACIP, both 1) health care personnel[SUP]?[/SUP] and 2) residents of long-term care facilities (LTCFs)[SUP]?[/SUP] be offered vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a**).[SUP]††[/SUP] In its deliberations, ACIP considered scientific evidence of SARS-CoV-2 epidemiology, vaccination program implementation, and ethical principles.[SUP]??[/SUP] The interim recommendation might be updated over the coming weeks based on additional safety and efficacy data from phase III clinical trials and conditions of FDA Emergency Use Authorization.
. 2020 Dec 11;69(49):1857-1859.
doi: 10.15585/mmwr.mm6949e1.
The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020
Kathleen Dooling, Nancy McClung, Mary Chamberland, Mona Marin, Megan Wallace, Beth P Bell, Grace M Lee, H Keipp Talbot, Jos? R Romero, Sara E Oliver
- PMID: 33301429
- DOI: 10.15585/mmwr.mm6949e1
Abstract
The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic that has disrupted all sectors of society. Less than 1 year after the SARS-CoV-2 genome was first sequenced, an application* for Emergency Use Authorization for a candidate vaccine has been filed with the Food and Drug Administration (FDA). However, even if one or more vaccine candidates receive authorization for emergency use, demand for COVID-19 vaccine is expected to exceed supply during the first months of the national vaccination program. The Advisory Committee on Immunization Practices (ACIP) advises CDC on population groups and circumstances for vaccine use.[SUP]†[/SUP] ACIP convened on December 1, 2020, in advance of the completion of FDA's review of the Emergency Use Authorization application, to provide interim guidance to federal, state, and local jurisdictions on allocation of initial doses of COVID-19 vaccine. ACIP recommended that, when a COVID-19 vaccine is authorized by FDA and recommended by ACIP, both 1) health care personnel[SUP]?[/SUP] and 2) residents of long-term care facilities (LTCFs)[SUP]?[/SUP] be offered vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a**).[SUP]††[/SUP] In its deliberations, ACIP considered scientific evidence of SARS-CoV-2 epidemiology, vaccination program implementation, and ethical principles.[SUP]??[/SUP] The interim recommendation might be updated over the coming weeks based on additional safety and efficacy data from phase III clinical trials and conditions of FDA Emergency Use Authorization.